3.連結財務諸表及び主な注記

(1)連結貸借対照表

 

 

(単位:千円)

 

前連結会計年度

(2025年3月31日)

当連結会計年度

(2026年3月31日)

資産の部

 

 

流動資産

 

 

現金及び預金

833,883

2,089,338

売掛金

98,855

103,542

仕掛品

46,115

22,777

原材料及び貯蔵品

32,755

39,662

前渡金

28,820

その他

65,266

54,527

流動資産合計

1,105,697

2,309,848

固定資産

 

 

有形固定資産

 

 

建物

254,674

255,030

減価償却累計額及び減損損失累計額

254,674

255,030

建物(純額)

機械及び装置

2,358

2,358

減価償却累計額及び減損損失累計額

2,358

2,358

機械及び装置(純額)

工具、器具及び備品

992,128

1,052,694

減価償却累計額及び減損損失累計額

992,128

1,052,694

工具、器具及び備品(純額)

有形固定資産合計

投資その他の資産

 

 

差入保証金

49,505

49,505

投資その他の資産合計

49,505

49,505

固定資産合計

49,505

49,505

資産合計

1,155,203

2,359,354

負債の部

 

 

流動負債

 

 

未払金

161,334

140,764

契約負債

142,054

12,106

未払法人税等

2,160

2,160

その他

22,189

14,936

流動負債合計

327,738

169,967

固定負債

 

 

長期未払金

51,067

資産除去債務

47,286

47,406

固定負債合計

98,353

47,406

負債合計

426,091

217,374

純資産の部

 

 

株主資本

 

 

資本金

50,000

50,000

資本剰余金

27,516,414

29,839,284

利益剰余金

26,908,248

27,818,886

自己株式

4

5

株主資本合計

658,161

2,070,392

新株予約権

70,950

71,588

純資産合計

729,111

2,141,980

負債純資産合計

1,155,203

2,359,354

 

E0536345640オンコセラピー・サイエンス株式会社OncoTherapy Science, Inc.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2025-04-012026-03-31FY2026-03-312024-04-012025-03-312025-03-311falsefalsefalse456402024-03-31jppfs_cor:SubscriptionRightsToSharesMember456402026-05-08456402026-03-31456402025-04-012026-03-31456402025-03-31456402024-04-012025-03-31456402024-03-31456402026-03-31jppfs_cor:TreasuryStockMember456402025-04-012026-03-31jppfs_cor:TreasuryStockMember456402025-03-31jppfs_cor:TreasuryStockMember456402024-04-012025-03-31jppfs_cor:TreasuryStockMember456402024-03-31jppfs_cor:TreasuryStockMember456402026-03-31jpcrp_cor:ReportableSegmentsMember456402026-03-31tse-acedjpfr-45640:ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember456402026-03-31tse-acedjpfr-45640:CancerPrecisionMedicalBusinessReportableSegmentsMember456402025-04-012026-03-31jpcrp_cor:ReportableSegmentsMember456402025-04-012026-03-31tse-acedjpfr-45640:ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember456402025-04-012026-03-31tse-acedjpfr-45640:CancerPrecisionMedicalBusinessReportableSegmentsMember456402025-04-012026-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember456402025-03-31jpcrp_cor:ReportableSegmentsMember456402025-03-31tse-acedjpfr-45640:ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember456402025-03-31tse-acedjpfr-45640:CancerPrecisionMedicalBusinessReportableSegmentsMember456402024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember456402024-04-012025-03-31tse-acedjpfr-45640:ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember456402024-04-012025-03-31tse-acedjpfr-45640:CancerPrecisionMedicalBusinessReportableSegmentsMember456402024-04-012025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember456402026-03-31jpcrp_cor:ReconcilingItemsMember456402025-04-012026-03-31jpcrp_cor:ReconcilingItemsMember456402025-03-31jpcrp_cor:ReconcilingItemsMember456402024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember456402024-03-31jppfs_cor:ShareholdersEquityMember456402024-03-31jppfs_cor:RetainedEarningsMember456402024-03-31jppfs_cor:CapitalSurplusMember456402024-03-31jppfs_cor:CapitalStockMember456402026-03-31jppfs_cor:SubscriptionRightsToSharesMember456402026-03-31jppfs_cor:ShareholdersEquityMember456402026-03-31jppfs_cor:RetainedEarningsMember456402026-03-31jppfs_cor:CapitalSurplusMember456402026-03-31jppfs_cor:CapitalStockMember456402025-04-012026-03-31jppfs_cor:SubscriptionRightsToSharesMember456402025-04-012026-03-31jppfs_cor:ShareholdersEquityMember456402025-04-012026-03-31jppfs_cor:RetainedEarningsMember456402025-04-012026-03-31jppfs_cor:CapitalSurplusMember456402025-04-012026-03-31jppfs_cor:CapitalStockMember456402025-03-31jppfs_cor:SubscriptionRightsToSharesMember456402025-03-31jppfs_cor:ShareholdersEquityMember456402025-03-31jppfs_cor:RetainedEarningsMember456402025-03-31jppfs_cor:CapitalSurplusMember456402025-03-31jppfs_cor:CapitalStockMember456402024-04-012025-03-31jppfs_cor:SubscriptionRightsToSharesMember456402024-04-012025-03-31jppfs_cor:ShareholdersEquityMember456402024-04-012025-03-31jppfs_cor:RetainedEarningsMember456402024-04-012025-03-31jppfs_cor:CapitalSurplusMember456402024-04-012025-03-31jppfs_cor:CapitalStockMemberxbrli:pureiso4217:JPY